Penlan Healthcare

What Penlan Healthcare does

Penlan Healthcare is a private UK pharmaceutical company headquartered in Weybridge, Surrey, that develops and markets generic and value-priced medicines across three therapeutic areas: Metabolism, Dermatology, and Ophthalmology. Founded in 2011 by Steve Martin (Member of the Royal Pharmaceutical Society) and Simon Raynor, the company targets market niches that are too small for established pharmaceutical companies to address. Its portfolio spans oral glucose tolerance testing (Rapilose OGTT, the first ready-made WHO-compliant solution launched in 2011), hypoglycaemia management (Rapilose Gel), dry eye treatment (ClinOptic HA preservative-free eye drops featuring the AeroPump dispenser delivering 350 drops per 10ml over 180 days), dermatological emollients (ExoCream, MyriBase Cream and Gel, Miclaro Oat Cream), nerve function support (Glaucomin Nicotinamide capsules), renal care (Renodyra potassium citrate modified release tablets, positioned as the first licensed UK presentation), and prescription-only products for acne and ocular surgical preparation (Adapalene/Benzoyl Peroxide Gel, Povidone Iodine 5%).

The business model combines prescription pharmaceutical sales through NHS pharmacies and wholesalers with over-the-counter consumer sales via a direct e-commerce storefront on penlanhealthcare.com. Products are priced 20-56% below originator brands, with NHS List Prices published for prescription items and consumer pricing ranging from £3.99 to £12.99. The company markets itself on generating NHS cost savings (over £21 million in portfolio-level potential), continuity of supply, and minimized packaging waste. Distribution occurs through the UK pharmacy network, mainline pharmaceutical wholesalers, and direct-to-consumer shipping.

Customer segments are NHS Healthcare Systems (primary), Healthcare Professionals including GPs, pharmacists, and specialists (primary), and patients as end consumers (secondary). The company operates two registered entities — Penlan Healthcare Limited and Penlan Pharmaceuticals Ltd — both in Weybridge. Strategic partnerships include trademark licensing arrangements with Pemberton Laboratories (ClinOptic) and Warneford Healthcare (Glaucomin). Growth signals include three prescription product launches in 2024-2026 and an international expansion page on the corporate website, though headcount remains small at 1-10 employees and revenue is not publicly disclosed.

Name

Penlan Healthcare

Legal name

Penlan Healthcare Limited

Website

https://penlanhealthcare.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Penlan Healthcare is a private UK pharmaceutical company that develops and markets generic, value-priced medicines in Metabolism, Dermatology, and Ophthalmology, selling to NHS systems, healthcare professionals, and consumers via pharmacies, wholesalers, and direct e-commerce.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Generic pharmaceuticals
• Prescription medicines
• Over-the-counter drugs
• Dermatology products
• Ophthalmic medicines

Headquarters

HQ city

Weybridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel, Infrastructure

Revenue model

1. Prescription Pharmaceutical Sales: Sale of prescription-only medicines to healthcare professionals and NHS systems through pharmacies and wholesalers.
2. Over-the-Counter Product Sales: Direct consumer sales of OTC/pharmacy-only medicines through the company's e-commerce platform and pharmacy partnerships.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Penlan Healthcare develops and markets generic and value pharmaceutical products across three therapeutic areas: Metabolism (diabetes care), Dermatology (emollients for dry skin and eczema), and Ophthalmology (preservative-free eye drops and surgical antiseptics). Products are sold on prescription through the NHS and UK pharmacy network, and over-the-counter via the company's direct e-commerce site.

Product overview

Penlan Healthcare is a private UK pharmaceutical company offering a portfolio of generic and value medicines across three therapeutic areas: Metabolism (diabetes care products including Rapilose® Gel for hypoglycaemia, Rapilose® OGTT for glucose tolerance testing, and Glaucomin™ Nicotinamide capsules), Dermatology (emollient products including ExoCream®, MyriBase® Cream, MyriBase® Gel, and Miclaro® Oat Cream for eczema and dry skin conditions), and Ophthalmology (ClinOptic® HA preservative-free eye drops for dry eye relief, and Povidone Iodine 5% for surgical preparation). The company also supplies Prescription Only Medicines including Renodyra® (potassium citrate for kidney stones) and Adapalene/Benzoyl Peroxide gel for acne. Products are available on prescription or for direct purchase, targeting both patients and healthcare professionals in the NHS.

Differentiator

Problem solved

Functional benefit

Brands

• Rapilose: Metabolism product line including Rapilose Gel (40% glucose gel for hypoglycaemia) and Rapilose OGTT (oral glucose tolerance test solution)
• ClinOptic
• ExoCream
• Glaucomin
• MyriBase
• Miclaro
• Renodyra

Products and services

• ClinOptic HA Eye-Drops

Quantifiable outcome

• Over £21 million in potential annual NHS savings across the product portfolio
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Pemberton Laboratories LimitedcoreTechnology or IntegrationPemberton Laboratories Limited is the owner of the ClinOptic® trademark. Penlan Healthcare distributes ClinOptic® HA Eye-Drops in the UK under this licensing arrangement.
• Warneford Healthcare LtdcoreTechnology or IntegrationWarneford Healthcare Ltd owns the Glaucomin™ trademark. Penlan Healthcare markets Glaucomin™ Capsules Nicotinamide B3 750mg under this arrangement.
• Thornton & Ross LimitedminorOthersCetraben® and ZeroBase® are trademarks of Thornton & Ross Limited. MyriBase® Cream is positioned as a generic alternative to Cetraben® Cream.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Others

• Alliance Healthcare (Walgreens Boots Alliance): UK pharmaceutical wholesaler and distributor used by Penlan to reach pharmacies; relevant channel-side peer shaping margin economics across the UK generics market.

Broad incumbents

• Thornton & Ross: Established UK OTC and generics manufacturer whose Cetraben® and ZeroBase® brands are the direct originator competitors Penlan positions MyriBase® against. Larger scale and broader portfolio make it a broad incumbent reference point.
• Sandoz (Novartis): One of the world's largest generic and biosimilar manufacturers with broad NHS supply contracts; relevant broad incumbent comparator in primary-care generics.
• Teva Pharmaceutical Industries: Global generic medicines leader with deep NHS presence; represents the competitive ceiling on pricing and supply reliability that any UK value-generic specialist must navigate.

Direct peers

• Aspire Pharma: UK-based niche pharmaceutical company focused on generic and value-added medicines supplied to the NHS across urology, dermatology and ophthalmology. Highly comparable in strategy and customer base to Penlan.
• Hylo (Scope Ophthalmics / Ursapharm): UK distributor of Ursapharm's Hylo-Tear and Hylo-Forte preservative-free sodium hyaluronate eye drops — the originator brand Penlan's ClinOptic is directly priced against.
• Morningside Pharmaceuticals: UK private pharma company supplying generic prescription and OTC medicines to the NHS and international markets, with a similar emphasis on affordable alternatives to originator products.
• Essential Pharma: Specialty pharma group focused on established, niche and legacy medicines often underserved by big pharma, including UK distribution — closely analogous to Penlan's niche-first strategy.
• Fontus Health: UK specialty pharma business marketing dermatology and consumer health products through pharmacy and NHS channels — directly comparable scale and channel mix to Penlan.
• Sovereign Medical: UK-based pharmaceutical supplier of generic and specialty medicines to the NHS, with overlapping therapeutic categories including dermatology and primary care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/61557663056876
• LinkedInlinkedin.com/company/penlan-pharmaceuticals-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Penlan Healthcare